Hereditary hemorrhagic telangiectasia (HHT), also known as Rendu-Osler-Weber syndrome, is a rare autosomal dominant vascular disorder. It is characterized by the presence of multiple arteriovenous malformations.^[@bibr1-2045894018759918]^ HHT is reported to be caused by mutations in the genes codifying for transforming growth factor β signaling receptors^[@bibr2-2045894018759918]^ and its estimated global prevalence was one patient per 5000--8000 inhabitants.^[@bibr3-2045894018759918]^ The clinical diagnosis of HHT is based on the four Curaçao criteria ([Table 1](#table1-2045894018759918){ref-type="table"}).^[@bibr4-2045894018759918]^ Table 1.Curaçao criteria for the clinical diagnosis of hereditary hemorrhagic telangiectasia (HHT).Curaçao criteria(1) spontaneous and recurrent epistaxis(2) multiple telangiectasia at characteristic sites(3) visceral lesions(4) a first-degree relative with HHT[^1]

Pulmonary arterial hypertension (PAH) is reported to be a rare manifestation of HHT, with prevalence of \< 1% of cases.^[@bibr5-2045894018759918]^ Recently, it is increasingly recognized as a severe complication of HHT. There have been a few case series describing the association between pulmonary hypertension (PH) and HHT. However, most of the studies recruited HHT patients with post-capillary PH.^[@bibr6-2045894018759918]^ The investigations of clinical characteristics and prognosis of PAH associated with HHT (HHT-PAH) are still very limited.

A few studies have reported the beneficial treatment effect of Bosentan or the combination of Bosentan and Sidenafil on HHT-PAH patients.^[@bibr7-2045894018759918],[@bibr8-2045894018759918]^ It also seems rational to treat HHT-PAH patients according to the PAH guidelines. However, clinical management experience for HHT-PAH patients is sparse as no long-term studies are available.

In this study, we aimed to describe the clinical and hemodynamic characteristics of a HHT-PAH cohort, which was confirmed by right heart catheterization (RHC), and to compare their long-term prognosis with a group of matched idiopathic pulmonary arterial hypertension patients (IPAH). In addition, we also wanted to illustrate the baseline characteristics which may predict the prognosis of HHT-PAH.

Methods {#sec1-2045894018759918}
=======

Patients who were diagnosed with HHT-PAH for the first time between October 2007 and January 2016 in Fuwai Hospital were prospectively recruited. The diagnosis of HHT was made according to the four Curaçao criteria.^[@bibr4-2045894018759918]^ The diagnosis of PAH was made in accordance with standard guidelines.^[@bibr9-2045894018759918]^ Clinical history, symptoms, signs, electrocardiograph (ECG), chest X-ray, transthoracic echocardiogram, pulmonary function test, high-resolution computed tomography (CT) of the chest, ventilation/perfusion scintigraphy lung scan, and pulmonary angiography (if necessary) were assessed to exclude PH due to left heart disease or lung diseases or chronic thromboembolism PH. The hemodynamic criteria for PAH included mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg, pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg, and pulmonary vascular resistance (PVR) ≥ 240 dyn·s·cm^--5^ measured at rest by RHC. Family HHT history was checked and additional specific diagnostic tests, including hematology, biochemistry, immunology, serology, and CT and ultrasonography of the abdomen, were performed to exclude other forms of PAH. Exclusion criteria included: (1) patients with other clinical types of PH; (2) patients who declined to participate in the study. For all HHT-PAH patients, matched IPAH patients, on cardiac index, mPAP, PVR, PCWP, and World Health Organization (WHO) functional class (FC), were recruited at the ratio of 2:1 (details about the recruitment of IPAH patients are shown in the supplementary material). Written informed consent was obtained from all enrolled patients. This study complied with the Declaration of Helsinki and was approved by the Institutional Review Board of Fuwai Hospital (ethical approval no. 402).

Clinical evaluation {#sec2-2045894018759918}
-------------------

Exercise capacity was evaluated by the WHO FC. The 6-min walk test was performed according to American Thoracic Society guidelines.^[@bibr10-2045894018759918]^ The algorithm incorporated 11 evaluable elements that were used to calculate REVEAL risk scores (RRS).^[@bibr11-2045894018759918]^ Data for diffusing capacity of the lung for carbon monoxide were not available for some of our patients; however, the RRS only requires 7/12 evaluable elements to maintain significant predictive power and calibration.^[@bibr11-2045894018759918]^ In this algorithm, calculated risks core could be in the range of 1 (lowest risk) to 21 (highest risk). For analysis of risk strata, patients were stratified into low (score 1--7), average (score 8) and higher stratum (score ≥ 9), based on their RRS, due to the small number of study patients. HHT-PAH and IPAH patients were also classified into low-risk, intermediate-risk, or high-risk groups according to European Respiratory Society (ERS) risk assessment.^[@bibr9-2045894018759918]^

Right heart catheterization {#sec3-2045894018759918}
---------------------------

Hemodynamic parameters including mean right atrial pressure (mRAP), mPAP, and PCWP were recorded during RHC. Cardiac output (CO) was measured by the thermodilution method (the mean value of three-time measurements). Body surface area (BSA) was calculated according to the Du Bois formula, i.e. BSA = 0.07184 × weight^0.425 ^× height^0.725^.^[@bibr12-2045894018759918]^ Cardiac index was calculated as CO/BSA. Pulmonary vascular resistance (PVR) was calculated using the following equation: PVR = (mPAP--PCWP)/CO. Diastolic pressure gradient (DPG) = diastolic PAP--mean PCWP. Pulmonary vasoreactivity testing was performed inhaling Iloprost. A positive acute response is defined as a reduction of mPAP ≥ 10 mmHg to reach an absolute value of mPAP ≤ 40 mmHg with an increased or unchanged CO.

Endpoint and follow-up {#sec4-2045894018759918}
----------------------

Each patient was followed up by telephone, outpatient, or in-hospital examinations in a six-month interval. They were included in this study from the date of signing informed consent till they had the primary outcome. The designed primary endpoint was any cause of mortality. None of the IPAH and HHT-PAH patients were lost to follow-up during the study period.

Statistics analysis {#sec5-2045894018759918}
-------------------

Continuous data were expressed as mean ± standard deviation (SD) and categorical data were expressed as frequency with percentage (%). Differences between the two groups were analyzed using the unpaired Student's t-test for continuous variables and Fisher's exact test for categorical variables. Univariate and multivariate Cox proportional hazards regression analyses were performed to identify independent variables associated with the endpoint. Results of these analyses were expressed as hazard ratio (HR) with 95% confidence interval (CI). Kaplan--Meier survival analyses were performed for the cumulative occurrence of endpoints. Between-group comparisons were made using the log-rank test. A value of *P* \< 0.05 was considered to indicate statistical significance. Statistical analyses were performed using SPSS 22.0 (SPSS, Inc., Chicago, IL, USA).

Results {#sec6-2045894018759918}
=======

Baseline demographic, clinical, and hemodynamic characteristics of HHT-PAH patients {#sec7-2045894018759918}
-----------------------------------------------------------------------------------

A total of 13 newly diagnosed HHT patients, who met the hemodynamic criteria of PAH, were recruited for this study. However, four HHT had increased cardiac index (≥4.0 L/min/m^2^).^[@bibr13-2045894018759918],[@bibr14-2045894018759918]^ Among these four patients, three had confirmed hepatic arteriovenous malformations (AVMs), which may lead to post-capillary PH because of high CO. Therefore, in order to be more precise and exclude the possibility of post-capillary PH, we decided to remove the four HHT patients with high CI. In the end, nine HHT patients with PAH were finally enrolled, including seven women and two men. Their mean age was 33.89 ± 10.00 years and 55.56% of them were WHO FC III. Among them, seven patients had a definite HHT diagnosis and two patients had a clinical possible HHT diagnosis (Suppl. Table S1).

The baseline characteristics of HHT-PAH patients are shown in [Table 2](#table2-2045894018759918){ref-type="table"}. All the enrolled patients had confirmed PAH, with mPAP 61.22 ± 19.73 mmHg, PCWP 8.89 ± 3.26 mmHg, and PVR 848.17 ± 378.34 dyn·s·cm^--5^. Interestingly, one patient had a positive result of acute vasoreactivity test, which had rarely been reported before. Pericardial effusions were detected by echocardiography in three patients. Six patients received PAH-specific drugs combined with conventional therapy as soon as their PAH diagnoses were confirmed. However, the other three patients only received conventional supportive therapy including diuretics, oxygen, and digoxin because of financial issues. The median follow-up time of HHT-PAH patients was 2.70 years (range = 0.77--7.70 years). During this period, five patients died because of right heart failure. Compared with survivors, deceased HHT-PAH patients had a lower ratio of direct and total bilirubin (D/TBil, 21.11 ± 4.72 versus 14.54 ± 2.26, *P* = 0.046). Table 2.Comparisons of baseline demographics, and clinical and hemodynamic characteristics between HHT-PAH and IPAH patients.HHT-PAHIPAH*P*Patients (n)918N/AAge (years)33.89 ± 10.0032.06 ± 9.180.638Female (%)7 (77.78)13 (72.22)N/ABody mass index (kg/m^2^)21.62 ± 3.5121.85 ± 3.690.876WHO FC I/II48N/AWHO FC III/IV5106MWD (m)385.00 ± 59.5469.27 ± 62.390.011[\*](#table-fn2-2045894018759918){ref-type="table-fn"}REVEAL risk score8.67 ± 2.297.11 ± 1.570.048[\*](#table-fn2-2045894018759918){ref-type="table-fn"}Low risk (n)3110.417Average risk (n)23High risk (n)44ERS risk group, low risk (n)250.951Intermediate risk (n)611High risk (n)12PAH-specific drug, yes (n)6170.093No (n)36Follow-up period (years) (Q1--Q3)2.70 (1.49--6.35)4.36 (2.70--5.99)0.537Deceased patient (n)530.072Hemodynamic characteristics by RHC SvO~2~ (%)71.60 ± 9.6773.63 ± 5.880.503 mRAP (mmHg)9.00 ± 5.506.72 ± 3.710.421 RVSP (mmHg)91.44 ± 29.7396.56 ± 28.810.671 RVEDP (mmHg)14.00 ± 6.6911.67 ± 6.670.400 PASP (mmHg)90.56 ± 30.3095.72 ± 27.040.657 PADP (mmHg)43.33 ± 14.3741.00 ± 16.020.716 mPAP (mmHg)61.22 ± 19.7361.06 ± 18.440.983 Cardiac index (L/min/m^2^)3.09 ± 0.553.08 ± 0.540.939 PCWP (mmHg)8.89 ± 3.267.78 ± 3.000.386 PVR (dyn·s·cm^--5^)848.17 ± 378.34966.08 ± 398.350.468 DPG (mmHg)34.44 ± 14.2933.22 ± 15.820.847 Pulmonary vasoreactivity test, positive (n)150.628 Negative (n)813Hemodynamic characteristics by echocardiography RVAPD (mm)34.67 ± 6.6728.56 ± 6.350.029[\*](#table-fn2-2045894018759918){ref-type="table-fn"} LAAPD (mm)30.00 ± 5.9327.00 ± 2.540.205 LVEDD (mm)38.67 ± 6.8937.06 ± 5.020.494 RV/LV (%)94.66 ± 29.3879.45 ± 24.120.191 LVEF (%)69.18 ± 6.0966.82 ± 5.630.328 Pericardial effusion, yes (n)330.367 No (n)615Blood gas analysis PH7.42 ± 0.037.42 ± 0.030.746 pCO~2~ (mmHg)32.12 ± 4.3835.11 ± 3.850.081 pO~2~ (mmHg)80.57 ± 8.8985.21 ± 17.760.470 SaO~2~ (%)95.97 ± 1.1195.91 ± 1.740.925Hematology RBC (10^12^/L)4.84 ± 0.905.06 ± 0.550.513 HGB (g/L)136.11 ± 27.75152.06 ± 14.760.137 HCT (%)42.86 ± 7.7145.11 ± 4.340.433 MCV (fl)89.36 ± 6.0989.79 ± 4.480.841 MCH (pg)28.46 ± 3.2030.12 ± 1.360.196 MCHC (g/L)317.38 ± 17.71335.72 ± 14.680.011[\*](#table-fn2-2045894018759918){ref-type="table-fn"} RDW (%)14.88 ± 2.9313.19 ± 0.830.031[\*](#table-fn2-2045894018759918){ref-type="table-fn"} PLT (10^9^/L)173.33 ± 38.79180.33 ± 54.110.733 PDW (%)13.71 ± 2.4314.34 ± 3.190.643Biochemistry ALT (IU/L)24.67 ± 12.7739.94 ± 32.070.091 AST (IU/L)26.11 ± 5.6527.78 ± 15.670.691 GGT (IU/L)31.00 ± 22.4639.83 ± 28.240.444 ALP (IU/L)66.25 ± 23.6182.33 ± 60.960.481 TBil (umol/L)25.73 ± 19.7320.00 ± 10.620.332 DBil (umol/L)3.39 ± 1.533.97 ± 2.650.569 D/TBil (%)17.82 ± 4.9119.39 ± 4.350.422 CREA (umol/L)63.66 ± 12.1666.40 ± 12.830.598 BUN (mmol/L)5.91 ± 1.385.06 ± 1.210.114 UA (umol/L)314.35 ± 135.3058363.17 ± 99.960.298 HSCRP (mg/L)2.79 ± 4.562.54 ± 3.140.870 CRP (mg/L)14.72 ± 30.193.67 ± 4.760.412 ESR (mm/h)5.11 ± 3.895.56 ± 5.060.819 LDH (IU/L)243.38 ± 81.84218.06 ± 47.990.338 PT (s)12.54 ± 4.8813.88 ± 1.400.283 PTA (%)80.00 ± 31.4792.11 ± 15.650.198 INR1.12 ± 0.167.06 ± 25.440.494 APTT (s)45.50 ± 15.5536.73 ± 3.560.157 NT-proBNP (fmol/mL)1558.81 ± 1152.301194.15 ± 776.980.409 Big ET (fmol/mL)0.58 ± 0.270.55 ± 0.510.887[^2][^3] Table 3.Baseline demographics, and clinical and hemodynamic characteristics of survival and deceased HHT-PAH patients.HHT-PAHSurvivorNon-survivor*P* Patients (n)45N/AAge (years)32.55 ± 11.5834.97 ± 9.860.744Body mass index (kg/m^2^)22.18 ± 4.6321.17 ± 2.830.698WHO FC I/II (n)22N/AWHO FC III/IV (n)236MWD (m)424.33 ± 47.59345.67 ± 44.120.104REVEAL risk score8.00 ± 2.839.20 ± 1.920.472Low risk (n)210.714Average risk (n)11High risk (n)13ERS risk group, low risk (n)200.165Intermediate risk (n)24High risk (n)01PAH-specific drug, yes (n)240.524No (n)21Follow-up period (years) (Q1--Q3)6.26 (3.41--7.44)2.18 (0.78--4.37)0.086Hemodynamic characteristics by RHC SvO~2~ (%)69.95 ± 10.6772.92 ± 9.830.670 mRAP (mmHg)7.25 ± 2.9910.40 ± 6.950.430 RVSP (mmHg)85.25 ± 33.4196.40 ± 29.360.610 RVEDP (mmHg)10.25 ± 1.5017.00 ± 7.910.141 PASP (mmHg)84.25 ± 31.2695.60 ± 32.110.611 PADP (mmHg)40.5 ± 10.5445.60 ± 17.760.630 mPAP (mmHg)58.00 ± 16.1563.80 ± 23.750.691 Cardiac index (L/min/m^2^)2.95 ± 0.553.21 ± 0.590.514 PCWP (mmHg)9.75 ± 3.788.20 ± 3.030.515 PVR (dyn·s·cm^--5^)879.61 ± 512.41823.02 ± 295.950.840 DPG (mmHg)30.75 ± 13.2537.40 ± 15.880.525 Pulmonary vasoreactivity test, positive (n)100.444Hemodynamic characteristics by echocardiography RVAPD (mm)33.00 ± 4.9736.00 ± 8.090.539 LAAPD (mm)29.25 ± 7.1430.75 ± 5.440.749 LVEDD (mm)39.5 ± 7.2338.00 ± 7.380.769 RV/LV (%)87.45 ± 29.4098.62 ± 31.760.605 LVEF (%)67.65 ± 5.1170.40 ± 7.090.537 Pericardial effusion, yes (n)120.595Blood gas analysis PH7.41 ± 0.027.40 ± 0.040.170 pCO~2~ (mmHg)34.78 ± 2.5130.00 ± 4.580.106 pO~2~ (mmHg)76.18 ± 5.3284.08 ± 10.110.203 SaO~2~ (%)95.30 ± 0.7196.50 ± 1.140.111Hematology RBC (10^12^/L)5.28 ± 0.754.48 ± 0.920.203 HGB (g/L)148.50 ± 35.35126.20 ± 18.080.256 HCT (%)46.53 ± 8.8639.92 ± 5.970.222 MCV (fl)87.58 ± 4.8591.15 ± 7.380.449 MCH (pg)27.83 ± 3.3529.10 ± 3.400.613 MCHC (g/L)316.25 ± 23.61318.50 ± 13.080.873 RDW (%)15.43 ± 3.8814.33 ± 2.050.634 PLT (10^9^/L)182.75 ± 54.91165.80 ± 24.250.551 PDW (%)15.00 ± 2.1712.75 ± 2.410.260Biochemistry ALT (IU/L)26.75 ± 17.6323.00 ± 9.220.691 AST (IU/L)22.25 ± 4.7929.20 ± 4.440.059 GGT (IU/L)41.25 ± 28.7420.75 ± 8.380.220 ALP (IU/L)77.00 ± 29.4455.50 ± 11.210.221 TBil (umol/L)16.20 ± 4.4833.35 ± 24.500.195 DBil (umol/L)3.51 ± 2.253.28 ± 0.570.850 D/TBil (%)21.11 ± 4.7214.54 ± 2.260.046[\*](#table-fn4-2045894018759918){ref-type="table-fn"} CREA (umol/L)65.76 ± 5.7961.98 ± 16.200.674 BUN (mmol/L)6.24 ± 1.745.64 ± 1.150.555 UA (umol/L)371.49 ± 166.014.78 ± 6.620.285 HSCRP (mg/L)26.90 ± 42.792.54 ± 1.450.428 CRP (mg/L)4.78 ± 6.621.20 ± 1.240.361 ESR (mm/h)6.00 ± 5.604.40 ± 2.300.621 LDH (IU/L)209.25 ± 26.99277.50 ± 108.600.301 PT (s)13.73 ± 1.3011.35 ± 7.080.534 PTA (%)93.75 ± 18.0366.25 ± 38.500.243 INR1.06 ± 0.141.16 ± 0.170.374 APTT (s)39.65 ± 3.6751.35 ± 21.430.323 NT-proBNP (fmol/mL)1387.95 ± 1425.411695.50 ± 1038.840.718 Big ET (fmol/mL)0.64 ± 0.350.54 ± 0.240.683[^4][^5]

Predictive value of TBil on the survival of HHT-PAH patients {#sec8-2045894018759918}
------------------------------------------------------------

Kaplan--Meier survival analysis showed the one- and three- year survival rates of HHT-PAH patients were 77.8% and 53.3%, respectively ([Fig. 1](#fig1-2045894018759918){ref-type="fig"}). Univariate Cox proportional hazards regression analyses determined that baseline total bilirubin (TBil) was a predictive factor for the primary endpoint (HR = 1.067, 95% CI = 1.003--1.135, *P* = 0.041; [Table 4](#table4-2045894018759918){ref-type="table"}). Considering the possible predictive values of age, WHO FC ≥ III, 6-min walk distance (6MWD), NT-proBNP, pericardial effusion, mRAP, cardiac index, mixed venous oxygen saturation (SvO~2~), and serum uric acid on the prognosis of PH patients,^[@bibr9-2045894018759918],[@bibr15-2045894018759918]^ these parameters were each examined with TBil using bivariate Cox proportional hazards regression analyses. Results showed that TBil still had the ability to independently predict the mortality of HHT-PAH patients after adjusting by age or SvO~2~ or cardiac index or serum uric acid ([Table 5](#table5-2045894018759918){ref-type="table"}). Fig. 1.Comparisons of Kaplan--Meier survival curves for PAH associated with HHT and matched IPAH patients (log rank: *P* = 0.047). Table 4.Univariate Cox proportional hazards regression analyses for primary endpoint of HHT-PAH patients.VariablesHazard ratio (95% CI)*P*Age0.982 (0.888--1.085)0.716WHO FC I/II1.708 (0.277--10.546)0.564REVEAL risk score1.548 (0.940--2.650)0.112ERS risk group93.99 (0.081--108827.28)0.2076MWD0.950 (0.888--1.018)0.145PAH-specific drug3.370 (0.357--31.853)0.289SvO~2~1.006 (0.912--1.109)0.907mRAP1.186 (0.933--1.508)0.163RVSP1.007 (0.974--1.042)0.664RVEDP1.204 (0.983--1.475)0.073PASP1.010 (0.977--1.044)0.572PADP1.042 (0.971--1.118)0.259mPAP1.020 (0.968--1.075)0.463PCWP0.792 (0.562--1.115)0.181PVR1.000 (0.998--1.003)0.718Cardiac index1.074 (0.175--6.594)0.938DPG1.054 (0.978--1.136)0.166RVAPD1.182 (0.960--1.455)0.115LAAPD0.984 (0.817--1.185)0.865LVEDD0.945 (0.821--1.087)0.427RV/LV1.026 (0.986--1.067)0.203LVEF1.164 (0.899--1.507)0.249Pericardial effusion0.147 (0.013--1.710)0.126pCO~2~0.796 (0.601--1.055)0.113pO~2~1.049 (0.956--1.150)0.313SaO~2~1.756 (0.750--4.113)0.195RBC0.546 (0.152--1.964)0.354HGB0.985 (0.952--1.018)0.365HCT0.830 (0.609--1.131)0.239MCV1.033 (0.862--1.238)0.725MCH1.057 (0.755--1.478)0.748MCHC1.010 (0.950--1.073)0.756RDW0.910 (0.629--1.316)0.616PLT0.995 (0.971--1.020)0.708PDW0.820 (0.524--1.284)0.386ALT0.999 (0.930--1.074)0.989AST1.355 (0.987--1.861)0.060GGT0.936 (0.788--1.112)0.452ALP0.921 (0.821--1.033)0.162TBil1.067 (1.003--1.135)0.041[\*](#table-fn6-2045894018759918){ref-type="table-fn"}DBil1.178 (0.628--2.209)0.609D/TBil0.666 (0.381--1.162)0.152CREA0.989 (0.884--1.106)0.843BUN0.643 (0.269--1.540)0.322CRP0.950 (0.819--1.103)0.501HSCRP0.816 (0.503--1.323)0.410UA0.998 (0.990--1.007)0.700LDH1.009 (0.997--1.021)0.156PT0.986 (0.830--1.171)0.870PTA0.995 (0.966--1.025)0.742INR3.944 (0.013--1241.199)0.640APTT0.954 (0.806--1.129)0.582ESR0.910 (0.712--1.163)0.450NT-proBNP1.000 (0.999--1.001)0.641[^6] Table 5.Multivariate Cox proportional hazards regression analyses for baseline characteristics to predict primary endpoints.VariableHazard ratio (95% CI)*P*TBil1.068 (1.002--1.137)0.042[\*](#table-fn7-2045894018759918){ref-type="table-fn"}Age1.009 (0.879--1.158)0.900TBil1.076 (1.002--1.155)0.044[\*](#table-fn7-2045894018759918){ref-type="table-fn"}SvO~2~1.045 (0.896--1.219)0.573TBil1.068 (1.004--1.136)0.038[\*](#table-fn7-2045894018759918){ref-type="table-fn"}CI1.300 (0.157--10.759)0.807TBil1.066 (1.001--1.136)0.048[\*](#table-fn7-2045894018759918){ref-type="table-fn"}UA1.000 (0.991--1.008)0.947TBil1.074 (0.995--1.160)0.068WHO functional class ≥ III0.655 (0.054--7.912)0.740TBil1.055 (0.987--1.127)0.118REVEAL risk score1.382 (0.732--2.610)0.319TBil1.214 (0.710--2.075)0.4796MWD0.885 (0.643--1.218)0.454TBil1.070 (0.997--1.149)0.062NT-proBNP1.000 (0.999--1.001)0.847TBil1.070 (0.991--1.156)0.084Pericardial effusion0.147 (0.009--2.505)0.185TBil1.082 (0.971--1.206)0.152mRAP0.933 (0.621--1.402)0.739[^7]

Comparisons between HHT-PAH and matched IPAH patients {#sec9-2045894018759918}
-----------------------------------------------------

A total of 18 matched IPAH patients were enrolled in this study and their median follow-up time was 4.36 years (range = 1.79--7.90 years). During this period, three of them died because of right heart failure. Kaplan--Meier survival analyses showed that HHT-PAH patients had a worse prognosis than matched IPAH patients (log rank: *P* = 0.047; [Fig. 1](#fig1-2045894018759918){ref-type="fig"}). Comparisons between these two cohorts showed that HHT-PAH patients had higher RRS score (8.67 ± 2.29 versus 7.11 ± 1.57, *P* = 0.048), worse 6MWD (385.00 ± 59.5 m versus 469.27 ± 62.39 m, *P* = 0.011), larger right ventricular anteroposterior diameter (RVAPD; 34.67 ± 6.67 mm versus 28.56 ± 6.35 mm, *P* = 0.029), wider red cell distribution width (RDW; 14.88 ± 2.93% versus 13.19 ± 0.83%, *P* = 0.031), and lower mean corpuscular hemoglobin concentration (MCHC; 317.38 ± 17.71 g/L versus 335.72 ± 14.68 g/L, *P* = 0.011) than matched IPAH patients ([Table 2](#table2-2045894018759918){ref-type="table"}).

Reassessment of HHT-PAH patients after long-term specific drug therapy {#sec10-2045894018759918}
----------------------------------------------------------------------

Four HHT-PAH patients had detailed clinical reassessments after receiving PAH-specific drug therapy (Suppl. Table S2). Among them, two received Sildenafil, one received Bosentan, and one had Diltiazem because of positive pulmonary vasoreactivity result. After treatment, one patient had improved WHO FC, two remained in the same condition, and one had deteriorated WHO FC. As for echocardiographic parameters, two patients had improved RV/LV, while two showed decreased RV/LV.

Discussion {#sec11-2045894018759918}
==========

Novel findings from the present study are that: (1) we reported the one- and three-year survival rates of HHT-PAH for the first time; (2) HHT-PAH patients might have a worse prognosis than matched IPAH patients; and (3) TBil might be a promising predictor for the long-term prognosis in HHT-PAH patients.

In the context of HHT, PH is categorized into two distinct types: pre- and post-capillary PH.^[@bibr5-2045894018759918],[@bibr16-2045894018759918]^ Post-capillary PH is considered to be associated with liver vascular malformations and secondary to high CO, typically after the onset of left heart failure,^[@bibr5-2045894018759918]^ while pre-capillary PH, which can also be called PAH in the context of HHT, is considered to be caused by pulmonary arteriopathy. HHT-PAH was thought to have largely increased PAP and PVR, increased transpulmonary gradient (TPG), decreased CO, and normal PCWP.^[@bibr5-2045894018759918]^ However, HHT with post-capillary PH was considered to have largely increased CO, increased PAP and PCWP, and normal TPG and PVR.^[@bibr5-2045894018759918]^ Recently, TPG has been replaced by DPG according to the new guideline.^[@bibr9-2045894018759918]^

In this study, we initially enrolled 13 HHT patients who met the hemodynamic criteria of PAH, with high mPAP, high PVR, and normal PCWP. However, four patients of this cohort had increased cardiac index (≥4.0 L/min/m^2^)^[@bibr13-2045894018759918]^ and three of the four patients had definite hepatic AVMs detected by abdominal CT. In order to exclude the possibility of PH induced by high CO, we decided to remove the four HHT patients with high cardiac index to get a pure HHT-PAH cohort.

PAH was considered as a rare complication of HHT and its exact prevalence in the HHT population has not been elucidated. Sopeña et al. found that combining with PH could significantly reduce survival rates of HHT patients.^[@bibr2-2045894018759918]^ There are previous studies which reported the long-term survival of individual HHT patients with PH^17^ or showed the survival of patients who had coexisting HHT and PH from any causes.^[@bibr14-2045894018759918]^ However, these studies did not report the survival rates of HHT-PAH patients. In this study, we found that the one- and three-year survival rates of HHT-PAH patients were 77.8% and 53.3%, respectively, which were much lower than the reported idiopathic/familial PAH survival rates by the REVEAL Registry study (the one- and three-year survival rates were 91% ± 2% and 74% ± 2%, respectively).^[@bibr18-2045894018759918]^ We then introduced a cohort of IPAH patients who matched with HHT-PAH patients on cardiac index, mPAP, PVR, PCWP, and WHO FC. Kaplan--Meier survival analyses between these two cohorts showed that HHT-PAH patients have a worse prognosis regardless of the same cardiopulmonary hemodynamic characteristics. By comparing the baseline characteristics of HHT-PAH and matched IPAH patients, we found that HHT-PAH patients had higher RRS, worse 6MWD, and larger RVAPD and RDW than matched IPAH patients. This explained why HHT-PAH patients had a worse prognosis on the one hand^[@bibr9-2045894018759918],[@bibr11-2045894018759918],[@bibr19-2045894018759918][@bibr20-2045894018759918]--[@bibr21-2045894018759918]^ and also indicated that HHT-PAH patients might have worse exercise tolerance, severe symptoms, and worse clinical condition even with the same cardiopulmonary hemodynamic characteristics as IPAH patients.

Another point we want to highlight here is that HHT-PAH patients had wider RDW and lower MCHC than matched IPAH patients and deceased HHT-PAH had lower D/TBil than survivors. These all suggested the possible existence of subclinical hemolysis in HHT-PAH, though the comparisons of hemoglobin, hematocrit, bilirubin, and lactate dehydrogenase (LDH) did not show statistical significances between these two groups. Over the last decade, there has been increasing interest in hemolysis as a potential cause of PH. Free hemoglobin, when released from the erythrocyte, reduces the bioavailability of nitric oxide (NO), and promotes endothelial dysfunction with thrombosis, inflammation, vasoconstriction, and smooth muscle proliferation in the capillaries.^[@bibr22-2045894018759918]^ Some studies have found that subclinical hemolysis plays important roles in the pathogenesis or pathophysiology of PAH^23,[@bibr24-2045894018759918]^ and may be associated with the severity of pulmonary vascular disease and clinical outcomes.^[@bibr22-2045894018759918]^ Though it is not possible to determine from the current study whether the subclinical hemolysis present in HHT-PAH patients represents a cause, effect, or epi-phenomenon of the illness, we suggested that subclinical hemolysis might be a feature of the HHT-PAH phenotype. Additional tests of hemolysis, including RBC lifespan or half-life (the golden standard), plasma-free hemoglobin, reticulocyte counts, erythrocyte creatine, and haptoglobin, are still needed to further confirm the values of subclinical hemolysis in HHT-PAH. Besides that, wider RDW and lower MCHC in HHT-PAH patients also suggested iron deficiency, which is highly prevalent in PAH and HHT and is associated with worse disease severity and clinical outcomes.^[@bibr13-2045894018759918],[@bibr25-2045894018759918]^ However, we did not measure markers of iron metabolism in this study.

Comparisons of baseline characters between survival and deceased HHT-PAH showed that non-survivors had lower D/TBil than survivors. Univariate and multivariate Cox proportional hazards regression analyses found that baseline TBil could predict the mortality of HHT-PAH patients independently, even after adjusting by age or SvO~2~ or cardiac index or serum uric acid. So HHT-PAH patients with higher TBil indicated worse prognosis. We thought this was partially due to hemolysis and previous studies have also identified TBil as a predictive risk factor for both systolic and diastolic heart failure and PAH because of hemodynamic alterations, including elevated central venous pressure and decreased cardiac index;^[@bibr26-2045894018759918][@bibr27-2045894018759918]--[@bibr28-2045894018759918]^ therefore, the recognition of liver dysfunction as a reflection of end-organ damage in right heart failure should also be paid much attention in HHT-PAH patients.

Even though there is no systematic evidence for the treatment of HHT-PAH at present, it seems rational to treat these patients with PAH-specific medication. Cases have reported the short-term or long-term effects of PAH-specific drugs (including bosentan, sildenafil, and epoprostenol) on HHT-PAH patients. It seemed that PAH-specific medication could improve the symptoms, exercise capacity, and cardiopulmonary hemodynamics of HHT-PAH patients.^[@bibr7-2045894018759918],[@bibr16-2045894018759918],[@bibr29-2045894018759918],[@bibr30-2045894018759918]^ However, in this study, reassessments of four HHT-PAH patients after receiving long-term PAH-specific drugs did not show significant clinical improvement in every patient. Besides that, these patients did not undergo a second RHC after receiving long-term PAH-specific drugs, so post-treatment cardiac index and PVR were unavailable. Therefore, strictly designed randomized controlled trials and pre- and post-treatment RHCs are still needed.

Our study had several limitations. First, this study consisted of patients referred to a single tertiary center, which may constitute a referral bias. Second, our center is a specialized hospital for cardiovascular diseases and all the recruited patients were suspected with PH, unknowing the diagnosis of HHT when they first came to us. Therefore, we cannot ascertain the exact prevalence of PAH in HHT. Third, gene mutation screening was not performed because of the expensive cost which was beyond most of the patients' affordability. Forth, detailed information of post PAH-specific drug therapy were only available in four patients, but no second RHC record. Consequently, we could not confirm the therapeutic effect of PAH specific drug on HHT-PAH patients. Fifth, the study population of HHT-PAH was limited and may reﬂect a relatively small sample of the entire HHT-PAH population. Given that PAH is a rare manifestation of HHT, with prevalence of \< 1% of HHT cases, it may be challenging to conduct large-scale studies. Finally, important parameters of hemolysis, including red blood cell lifespan or half-life (the golden standard test), plasma-free hemoglobin, reticulocyte counts, erythrocyte creatine, haptoglobin, and parameters reflecting iron metabolism, were also needed to confirm the values of iron deficiency and subclinical hemolysis in HHT-PAH patients.

In conclusion, the one- and three-year survival rates of HHT-PAH patients were 77.8% and 53.3%, respectively, which were worse than matched IPAH patients. Total bilirubin might be a promising predictor for the long-term prognosis in HHT-PAH patients.
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[^1]: A definite diagnosis of HHT needs to meet at least three criteria; meeting two criteria is considered as a clinical "possible" HHT; only meeting one or no criterion makes the diagnosis "unlikely."

[^2]: *P* \< 0.05.

[^3]: NA, not applicable; PAH, pulmonary arterial hypertension; IPAH, idiopathic pulmonary arterial hypertension; WHO FC, World Health Organization functional class; 6MWD, 6-min walk distance; ERS, European Respiratory Society; RHC, right heart catheterization; SvO~2~, mixed venous oxygen saturation; mRAP, mean right atrial pressure; RVSP, right ventricle systolic pressure; RVEDP, right ventricle end diastolic pressure; PASP, pulmonary arterial systolic pressure; PADP, pulmonary arterial diastolic pressure; mPAP, mean pulmonary arterial pressure; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; DPG, diastolic pressure gradient; RVAPD, right ventricular anteroposterior diameter; LAAPD, left atrial anteroposterior diameter; LVEDD, left ventricular end diastolic diameter; RV/LV, RVAPD/ LAAPD; LVEF, left ventricular ejection fraction; pCO~2~, partial pressure of carbon dioxide; pO~2~, partial pressure of oxygen; SaO~2~, arterial oxygen saturation; RBC, red blood cell count; HGB, hemoglobin; HCT, hematocrit; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; RDW, red cell distribution width; PLT, platelets count; PDW, platelet distribution width; ALT, glutamic-pyruvic transaminase; AST, aspartate amino transferase; GGT, gamma-glutamyl transpeptidase; ALP, alkaline phosphatase; Tbil, total bilirubin; Dbil, direct bilirubin; D/TBil, total bilirubin/direct bilirubin; CREA, creatinine; BUN, blood urea nitrogen; UA, uric acid; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; LDH, lactate dehydrogenase; PT, prothrombin time; PTA, prothrombin time activity percentage; INR, international normalized ratio; APTT, activated partial thromboplastin time; NT-proBNP, N terminal pro-brain natriuretic peptide; big-ET, big endothelin.

[^4]: *P* \< 0.05.

[^5]: NA, not applicable; PAH, pulmonary arterial hypertension; IPAH, idiopathic pulmonary arterial hypertension; WHO FC, World Health Organization functional class; 6MWD, 6-min walk distance; ERS, European Respiratory Society; RHC, right heart catheterization; SvO~2~, mixed venous oxygen saturation; mRAP, mean right atrial pressure; RVSP, right ventricle systolic pressure; RVEDP, right ventricle end diastolic pressure; PASP, pulmonary arterial systolic pressure; PADP, pulmonary arterial diastolic pressure; mPAP, mean pulmonary arterial pressure; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; DPG, diastolic pressure gradient; RVAPD, right ventricular anteroposterior diameter; LAAPD, left atrial anteroposterior diameter; LVEDD, left ventricular end diastolic diameter; RV/LV, RVAPD/ LAAPD; LVEF, left ventricular ejection fraction; pCO~2~, partial pressure of carbon dioxide; pO~2~, partial pressure of oxygen; SaO~2~, arterial oxygen saturation; RBC, red blood cell count; HGB, hemoglobin; HCT, hematocrit; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; RDW, red cell distribution width; PLT, platelets count; PDW, platelet distribution width; ALT, glutamic-pyruvic transaminase; AST, aspartate amino transferase; GGT, gamma-glutamyl transpeptidase; ALP, alkaline phosphatase; Tbil, total bilirubin; Dbil, direct bilirubin; D/TBil, total bilirubin/direct bilirubin; CREA, creatinine; BUN, blood urea nitrogen; UA, uric acid; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; LDH, lactate dehydrogenase; PT, prothrombin time; PTA, prothrombin time activity percentage; INR, international normalized ratio; APTT, activated partial thromboplastin time; NT-proBNP, N terminal pro-brain natriuretic peptide; big-ET, big endothelin.

[^6]: *P* \< 0.05.

[^7]: *P* \< 0.05.
